Clinical data | |
---|---|
Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H32FN5O2 |
Molar mass | 453.562 g·mol−1 |
3D model ( JSmol) | |
| |
|
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression. [1] [2] [3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder. [1] [2] [3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication. [4]
Clinical data | |
---|---|
Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H32FN5O2 |
Molar mass | 453.562 g·mol−1 |
3D model ( JSmol) | |
| |
|
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression. [1] [2] [3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder. [1] [2] [3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication. [4]